International Journal of Drug Delivery Technology
Volume 14, Issue 3

Design and Development of Solid Lipid Nanoparticles of Tofacitinib Citrate for the Treatment of Rheumatoid Arthritis: A Quality by Design Approach

V Deepika1*, S Srinu Naik2

1Department of Pharmacy, University College of Technology, Osmania University, Hyderabad, Telangana, India.

2Department of Chemical Engineering, University College of Technology, Osmania University, Hyderabad, Telangana, India. 

Received: 24th February, 2024; Revised: 18th April, 2024; Accepted: 10th June, 2024; Available Online: 25th September, 2024 

ABSTRACT

Solid lipid nanoparticles, or SLNs, have gained popularity recently as a possible drug delivery method. However, the idea of using SLNs for organ and site-specific drug administration is still in its early stages due to the difficulties associated with this approach. The aim of this study is to develop SLNs with improved pharmaceutical characterization and anti-arthritic efficacy. Tofacitinib citrate (TC)-loaded SLNs were created using the microemulsification method, with the addition of stearic acid, chitosan, and Tween 80 to improve skin permeability. Seventeen SLNs were developed and characterized for particle size, entrapment efficiency (EE), and percentage drug release according to the Box-Behnken design. The DSC analysis revealed a strong endothermic peak at 166.18°C, significantly different from the pure TC reported at 218.05°C. This indicates a notable alteration in the endothermic peak of the SLNs, demonstrating a relationship with the excipients used in this investigation. XRD study highlighted significant characteristic drug peaks at positions 21.06 and 23.63 (2ɵ). These peaks represented the modifications that were seen in pure TC. The SEM analysis of the optimized lipid nanoparticles showed a smooth surface and a spherical appearance. The particle size analysis of the optimized formulation showed an average size of 181.5 nm. Also, the polydispersity index (PI) revealed a value of 0.495, indicating homogeneous dispersion. The zeta value was 8.2 mV, indicating stability.

Keywords: Tofacitinib citrate, Micro emulsification, Solid lipid nanoparticles, Box-Behnken design, Stability International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.3.31

How to cite this article: Deepika V, Naik SS. Design and Development of Solid Lipid Nanoparticles of Tofacitinib Citrate for the Treatment of Rheumatoid Arthritis: A Quality by Design Approach. International Journal of Drug Delivery Technology. 2024;14(3):1479-1486.

REFERENCES

  1. Taylor P.C., Moore A., Vasilescu R., Alvir J., Tarallo M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current Rheumatol. Int. 2016;36(5):685–695.
  2. S, Dr. R. Shyam Sunder. A Novel Nasal Fluoxetine loaded Solid Lipid Nanoparticles in Mucoadhesive in situ gel Formulation for brain targeting: Preparation, Characterization and in vivo evaluation. YMER. 2022; 21(9):433-452.
  3. Dorner , Strand V., Cornes P., Goncalves J., Gulacsi L., Kay J., Kvien T.K., Smolen J., Tanaka Y., Burmester G.R. The changing landscape of biosimilars in rheumatology. Ann. Rheum Dis. 2016;75(6):974–982.
  4. Weber, , Zimmer, A., & Pardeike, J. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: A review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics. 2014; 86(1), 7–22
  5. Babu VN, Rao GSNK, Budha RR, Alavala RR, Desu PK, Babu GK, Prasad AD. Development, characterization and optimization of solid lipid nanoparticles of alpha-mangostin by central composite design approach. J Appl Pharm Sci, 2023; 13(08):140–150.
  6. Swagata Patra, Joyk r ishna Dey, Avik Chak rabor t Physicochemical Characterization, Stability, and In-vitro Evaluation of Curcumin-Loaded Solid Lipid Nanoparticles Prepared Using Biocompatible Synthetic Lipids. ACS Applied Bio Materials. 2023; 6 (7): 2785-2794.
  7. Michael Jackson Ferreira da Silva, Alisson Mendes Rodrigues, Maria Célia Pires Costa, Adriana Leandro Solid Lipid Nanoparticles Based on Babassu Oil and Copaiba Oleoresin: A Promising Approach for Prostate Cancer Therapy. Nanomaterials 2024, 14 (12) , 1014.
  8. Bhamidipati PK, Kantarjian H, Cortes J, Cornelison AM, Jabbour
  9. Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol. 2013;4(2):103-17.
  10. Xia B, Heimbach T, He H, Lin TH. Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic Biopharm Drug Dispos. 2012;33(9):536-49.
  11. Tanaka MF, Kantarjian H, Cortes J, Ohanian M, Jabbour E. Treatment options for chronic myeloid leukemia. Expert Opin Pharmacother. 2012 Apr 1;13(6):815-28.
  12. Markovic M, Ben-Shabat S, Aponick A, Zimmermann EM, Dahan Lipids and lipid-processing pathways in drug delivery and therapeutics. Int J Mol Sci. 2020 Jan;21(9):3248.
  13. Kakodkar S, Sharmada S. Pharmaceutical quality-by-design (QbD): basic principles. Int J Res Methodol. 2015;1(1).
  14. Grana A, Limpach A, Chauhan H. Formulation considerations and applications of solid lipid nanoparticles. Am Pharm Rev. 2013;16(1):19-25.
  15. Pooja D, Kulhari H, Tunki L, Chinde S, Kuncha M, Grover P, Rachamalla SS, Sistla Nanodrugs for targeted delivery of etoposide to non-small cell lung cancer using transferrin- functionalized nanoparticles. RSC Adv. 2015;5(61):49122-31.
  16. Barman RK, Iwao Y, Funakoshi Y, Ranneh AH, Noguchi S, Wahed MI, Itai Development of highly stable nifedipine solid lipid nanoparticles. Chem Pharm Bull (Tokyo). 2014;62(5):399- 406.
  17. Shen J, Burgess In-vitro dissolution testing strategies fornanoparticulate drug delivery systems: recent developments and challenges. Drug Deliv Transl Res. 2013;3(5):409-15.
  18. Begum MY, Gudipati PR. Formulation and evaluation of dasatinib-loaded solid lipid nanoparticles. Int J Pharm Pharm Sci. 2018;10(12):14.
  19. Taraka Sunil Kumar K, Mohan Varma M, Ravi Prakash. Development and optimization of enzalutamide-loaded solid lipid nanoparticles using box–behnken design. Asian J Pharm Clin Res. 2019;12:67-76.
  20. Sawant P, Karekar P, Waghmare Formulation and characterization of solid lipid nanoparticles containing ginger oil for enhancement of stability. Int J Pharm Pharm Sci. 2020;12(6):36-44.
  21. Fearon U., Canavan M., Biniecka M., Veale D.J. Hypoxia, mitochondrial dysfunction and synovial invasiveness in rheumatoid arthritis. Nat. Rev. Rheumatol. 2016;12:385–397.
  22. Shyam Sunder, Vasudha Bakshi. Design, in-vitro characterization & optimization of mefenamic acid-loaded carboxy methyl chitosan nanoparticles. Journal of Global Trends in Pharmaceutical Sciences. 2020; 11(1):7290-7297.
  23. Svendsen A.J., Junker P., Houen G., Kyvik K.O., Nielsen C., Skytthe , Holst R. Incidence of chronic persistent rheumatoid arthritis and the impact of smoking: a historical twin cohort study. Arthritis Care Res. 2016;69(5):616–624.
  24. Yang , Feng X., Ding J., Chang F., Chen X. Nanotherapeutics relieve rheumatoid arthritis. J. Control Release. 2017;252:108– 124.
  25. McInnes B., Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389:2328–2337.
  26. Ursini , Leporini C., Bene F., D’Angelo S., Mauro D., Russo E., De Sarro G., Olivieri I., Pitzalis C., Lewis M., Grembiale R.D. Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysis. Sci. Rep. 2017;7:5346.
  27. Tanaka Y. Current concepts in the management of rheumatoid arthritis. Korean J. Intern. Med. 2016;31(2):210–218.
  28. McInnes B., Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 2017;389:2328–2337.
  29. Jones , Nash P., Hall S. Advances in rheumatoid arthritis. Med. J Aust. 2017;206(5):221–224.
  30. Dodle Trishala, Bichitrananda Tripathy, Swapna S. A Critical Review on Phytosomes: Advancement and Research on Emerging Nanotechnological Current Bioactive Compounds.2023;19(5):89-99.
  31. Rajkumar, Dr.Akiful Haque, Swapna.S. Characterization and Optimization of Hydrogel Films Loaded with a Hydrophobic Drug. Eur. Chem. Bull.2023; 12(9):3347-3363.
  32. Bhalekar M.R., Madgulkar A.R., Desale P.S., Marium G. Formulation of piperine solid lipid nanoparticles (SLN) for treatment of rheumatoid Drug. Dev. Ind Pharm.2017;43(6):1003–1010.
  33. Raj , Mongia P., Ram A., Jain N.K. Enhanced skin delivery of aceclofenac via hydrogel-based solid lipid nanoparticles. Artif. Cells Nanomed. Biotechnol. 2016;44(6):1434–1439.
  34. Garg K., Singh B., Tyagi R.K., Sharma G., Katare O.P. Effective transdermal delivery of methotrexate through nanostructured lipid carriers in an experimentally induced arthritis model. Colloids Surf. B Biointerfaces. 2016;147:17–24.
  35. Chavan , Gangode B., Jadhav A., Patil M., Kshirsagar S. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. IJOD. 2017;5(2):56–70.
  36. Panahi , Farshbaf M., Mohammadhosseini M., Mirahadi M., Khalilov R., Saghfi S., Akbarzadeh A. Recent advances on liposomal nanoparticles: synthesis, characterization and biomedical applications. Artif. Cells Nanomed. Biotechnol. 2017;45(4):788–799.
  37. Saitejaswi, Swapna. S. Formulation and Evaluation of Lornoxicam loaded Transfersome gel. European Journal of Biomedical and Pharmaceutical Sciences. 2016; 3(3):144-150
  38. Heloise R., Danhier F., Preat V., Langer R., Anderson D.G. Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field Expert Opion Drug Deliv. 2017;14(7):851–864.
  39. Nagendrababu, Vasudha Bakshi. Augmentation of Solubility of Carvedilol Phosphate by Solid Dispersions Using Skimmed Milk. Indo-American Journalof Pharmaceutical Research. 2015; 5: 3521-27
  40. Dolati S., Sadreddini S., Rostamzadeh D., Ahmadi M., Jadidi- Niaragh F., Yousefi M. Utilization of nanoparticle technology in rheumatoid arthritis treatment. Biomed. Pharmacother. 2016;80:30–41.
  41. Nogueira E., Gomes A.C., Preto A., Cavaco-Paulo A. Folate- targeted nanoparticles for rheumatoid arthritis Nanodrug. 2016;12(4):1113–1126.
  42. Bianchi G., Caporali R., Todoerti M., Mattana P. Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of Adv. Ther. 2016;33(3):369– 378.
  43. Li Z., Xu X.H., Lin N., Lu H.D. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann. Rheum Dis. 2018;77(1):98–103.
  44. Bahadar H., Maqbool F., Niaz K., Abdollahi M. Toxicity of nanoparticles and an overview of current experimental models. Iran Biomed. J. 2016;20(1):1–11.
  45. Ramaiah Maddi, Balaji Maddiboyina, Ramya Krishna Nakkala, Harekrishna Roy, M Akiful Haque, Azmath Farhana, & Swapna
  46. Exploring the Therapeutic Potential of Probiotics in Fighting Respiratory Viral Infections. Journal of Population Therapeutics and Clinical Pharmacology, 2022; 29(04), 886–900.